Skip to main content
Cyber Week Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Buy” From Brokerages

Summary by themarketsdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been assigned an average rating of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

themarketsdaily.comthemarketsdaily.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Buy” from Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been assigned an average rating of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

themarketsdaily.com broke the news in on Friday, December 5, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Novato icon

Novato

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal